Figure 1 | Scientific Reports

Figure 1

From: Safety and tolerability of topically administered autologous, apoptotic PBMC secretome (APOSEC) in dermal wounds: a randomized Phase 1 trial (MARSYAS I)

Figure 1

CONSORT Study Design of MARSYAS. The screening and design of the study were developed and conducted by the Department of Clinical Pharmacology of the Medical University of Vienna. Ten participants were included after giving written informed consent. Allocation to the low-dose group A and high-dose group B was completed after an interim analysis. To avoid inter-individual differences, every study participant received both verum and placebo on different positions on the same arm. The randomization of verum and placebo to the proximal or distal artificial arm wound was performed in a 1:1 ratio.

Back to article page